Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Myeloid blast crisis evolving during imatinib treatment of an FIP1L1-PDGFR alpha-positive chronic myeloproliferative disease with prominent eosinophilia.

× No keyword cloud information.

16 in total

Review 1. Eosinophilic myeloproliferative disorders.

Authors: Amy D Klion
Journal: Hematology Am Soc Hematol Educ Program Date: 2011

2. Discovery of a small-molecule type II inhibitor of wild-type and gatekeeper mutants of BCR-ABL, PDGFRalpha, Kit, and Src kinases: novel type II inhibitor of gatekeeper mutants.

Authors: Ellen Weisberg; Hwan Geun Choi; Arghya Ray; Rosemary Barrett; Jianming Zhang; Taebo Sim; Wenjun Zhou; Markus Seeliger; Michael Cameron; Mohammed Azam; Jonathan A Fletcher; Maria Debiec-Rychter; Mark Mayeda; Daisy Moreno; Andrew L Kung; Pasi Antero Janne; Roya Khosravi-Far; Junia V Melo; Paul W Manley; Sophia Adamia; Catherine Wu; Nathanael Gray; James D Griffin
Journal: Blood Date: 2010-03-18 Impact factor: 22.113

Review 3. Biological Modulators in Eosinophilic Diseases.

Authors: Panida Sriaroon; Mark Ballow
Journal: Clin Rev Allergy Immunol Date: 2016-04 Impact factor: 8.667

4. Sorafenib is a potent inhibitor of FIP1L1-PDGFRalpha and the imatinib-resistant FIP1L1-PDGFRalpha T674I mutant.

Authors: Els Lierman; Cedric Folens; Elizabeth H Stover; Nicole Mentens; Helen Van Miegroet; Werner Scheers; Marc Boogaerts; Peter Vandenberghe; Peter Marynen; Jan Cools
Journal: Blood Date: 2006-04-27 Impact factor: 22.113

Review 5. Primary eosinophilic disorders: a concise review.

Authors: Animesh Pardanani; Ayalew Tefferi
Journal: Curr Hematol Malig Rep Date: 2008-01 Impact factor: 3.952

6. F604S exchange in FIP1L1-PDGFRA enhances FIP1L1-PDGFRA protein stability via SHP-2 and SRC: a novel mode of kinase inhibitor resistance.

Authors: S P Gorantla; K Zirlik; A Reiter; C Yu; A L Illert; N Von Bubnoff; J Duyster
Journal: Leukemia Date: 2015-03-12 Impact factor: 11.528

7. Clonal hypereosinophilic syndrome: two cases report in black men from sub-saharan Africa and literature reviews.

Authors: Kodjovi Messie; Ahoefa Vovor; Irenee Messanh Kueviakoe; Levi Kankoe Sallah; Kossi Agbetiafa; Akuete Yvon Segbena
Journal: ISRN Hematol Date: 2011-03-22

Review 8. Hypereosinophilic syndromes.

Authors: Florence E Roufosse; Michel Goldman; Elie Cogan
Journal: Orphanet J Rare Dis Date: 2007-09-11 Impact factor: 4.123

9. The conformational control inhibitor of tyrosine kinases DCC-2036 is effective for imatinib-resistant cells expressing T674I FIP1L1-PDGFRα.

Authors: Yingying Shen; Xiaoke Shi; Jingxuan Pan
Journal: PLoS One Date: 2013-08-29 Impact factor: 3.240

10. Myeloid Neoplasm with PDGFRA Rearrangement Manifesting as a Retromolar Pad Mass.

Authors: Amy S Duffield; Jonathan Webster; B Douglas Smith; Julius S Necciai; Austin McCuiston; Alisha D Ware
Journal: Head Neck Pathol Date: 2021-02-22